This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Magnesium phosphate is a supplement indicated in the treatment of magnesium deficiency.
- Generic Name
- Magnesium phosphate
- DrugBank Accession Number
- DB13862
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Magnesium phosphate (DB13862)
- Weight
- Average: 262.858
Monoisotopic: 261.861965694 - Chemical Formula
- Mg3O8P2
- Synonyms
- Magnesium phosphate (3:2)
- Magnesium phosphate anhydrous
- Magnesium phosphate, tribasic
- Magnesium phosphate, tribasic, anhydrous
- Phosphoric acid, magnesium salt (2:3)
- Tertiary magnesium phosphate
- Trimagnesium phosphate
- External IDs
- E-343(III)
- INS NO.343(III)
- INS-343(III)
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Magnesium deficiency Combination Product in combination with: Magnesium citrate (DB11110) ••• ••• ••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAtracurium The therapeutic efficacy of Atracurium can be increased when used in combination with Magnesium phosphate. Atracurium besylate The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium phosphate. Botulinum toxin type A The therapeutic efficacy of Botulinum toxin type A can be increased when used in combination with Magnesium phosphate. Botulinum toxin type B The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Botulinum toxin type B. Capreomycin The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Magnesium phosphate. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Magnesium phosphate dibasic trihydrate HF539G9L3Q 7782-75-4 OKIWLDVQGKRUNR-UHFFFAOYSA-L Magnesium phosphate pentahydrate 453COF7817 10233-87-1 QZYXGKYJDBUYES-UHFFFAOYSA-H - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image BIOMAGNESIN Magnesium phosphate dibasic trihydrate (265 mg/1) + Magnesium (42.9 mg/1) Lozenge Oral 2006-07-01 Not applicable Germany 
BIOMAGNESIN Magnesium phosphate dibasic trihydrate (265 mg/1) + Magnesium (42.9 mg/1) Lozenge Oral 2006-07-01 Not applicable Germany BLACKMORES EXECUTIVE B TABLET Magnesium phosphate (175 mg) + Ascorbic acid (180 mg) + Biotin (50 µg) + Cyanocobalamin (10 µg) + Folic acid (200 mcg) + Nicotinamide (60 mg) + Pantothenic acid (20 mg) + Potassium sulfate (75 mg) + Pyridoxine hydrochloride (10 mg) + Riboflavin (8.5 mg) + Thiamine mononitrate (7.5 mg) + Zinc sulfate (15 mg) Tablet Oral BLACKMORES (MALAYSIA) SDN. BHD. 2020-09-08 Not applicable Malaysia 
Categories
- ATC Codes
- B05XA10 — Magnesium phosphate
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as alkaline earth metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkaline earth metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Alkaline earth metal oxoanionic compounds
- Sub Class
- Alkaline earth metal phosphates
- Direct Parent
- Alkaline earth metal phosphates
- Alternative Parents
- Inorganic salts / Inorganic oxides
- Substituents
- Alkaline earth metal phosphate / Inorganic oxide / Inorganic salt
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- XMK14ETW2D
- CAS number
- 7757-87-1
- InChI Key
- GVALZJMUIHGIMD-UHFFFAOYSA-H
- InChI
- InChI=1S/3Mg.2H3O4P/c;;;2*1-5(2,3)4/h;;;2*(H3,1,2,3,4)/q3*+2;;/p-6
- IUPAC Name
- trimagnesium(2+) diphosphate
- SMILES
- [Mg++].[Mg++].[Mg++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O
References
- General References
- DIMDI Product Information: BIOMAGNESIN (magnesium citrate and magnesium phosphate ) oral lozenge [Link]
- External Links
- ChemSpider
- 22847
- 29164
- ChEMBL
- CHEMBL2106873
- Wikipedia
- Magnesium_phosphate
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Lozenge Oral Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -1 Chemaxon pKa (Strongest Acidic) 1.8 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 86.25 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 11.29 m3·mol-1 Chemaxon Polarizability 4.93 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 105.5384532 predictedDarkChem Lite v0.1.0
Drug created at June 26, 2017 20:08 / Updated at May 21, 2021 10:23